Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
$8.73
-4.1%
$7.60
$4.66
$9.90
$143.39M0.6816,520 shs11,508 shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$15.56
+2.6%
$14.04
$9.12
$72.37
$631.97M1.33456,951 shs675,014 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.89
+9.4%
$4.30
$2.45
$6.71
$620.34M1.76691,533 shs1.26 million shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$6.93
+2.5%
$5.27
$1.87
$11.40
$606.45M-0.051.15 million shs1.30 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
0.00%-6.33%+11.21%+38.79%+872,999,900.00%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
0.00%+7.46%+8.21%+6.79%-66.85%
Organogenesis stock logo
ORGO
Organogenesis
0.00%+3.38%+2.95%+68.62%+72.79%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%-1.70%+14.36%+129.47%-12.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
3.012 of 5 stars
3.32.00.00.03.33.30.6
Organogenesis stock logo
ORGO
Organogenesis
4.2927 of 5 stars
3.31.00.04.32.64.20.6
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.7615 of 5 stars
3.31.00.04.11.93.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
3.00
Buy$13.6756.55% Upside
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.50
Moderate Buy$30.0092.80% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$7.5053.37% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63125.47% Upside

Current Analyst Ratings Breakdown

Latest BHST, ORGO, TERN, and KROS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $20.00
8/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$7.00 ➝ $9.00
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
6/10/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$32.00 ➝ $18.00
5/30/2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$15.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
$25.19M5.69N/AN/A($0.26) per share-33.58
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$3.55M178.04N/AN/A$17.40 per share0.89
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.29$0.21 per share23.43$1.84 per share2.66
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$3.49 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$12.91M-$0.70N/AN/AN/A-39.95%-11,357.84%-39.94%N/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$187.35M$0.3150.20N/A1.918.06%2.96%2.74%11/5/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/11/2025 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$88.85M-$1.04N/AN/AN/AN/A-27.35%-26.18%11/11/2025 (Estimated)

Latest BHST, ORGO, TERN, and KROS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$0.1075-$0.15-$0.0425-$0.24$8.53 million$8.52 million
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
8/6/2025Q2 2025
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 million
8/5/2025Q2 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.28-$0.26+$0.02-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
0.60
0.36
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/A
21.11
21.11
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
24.70
24.70

Institutional Ownership

CompanyInstitutional Ownership
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
71.56%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
20.60%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A16.42 millionN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
10040.62 million32.25 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.51 million86.20 millionNot Optionable

Recent News About These Companies

Terns (TERN) Q2 Net Loss Narrows 16%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioHarvest Sciences stock logo

BioHarvest Sciences NASDAQ:BHST

$8.73 -0.37 (-4.07%)
As of 08/22/2025 03:54 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Keros Therapeutics stock logo

Keros Therapeutics NASDAQ:KROS

$15.56 +0.39 (+2.57%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$15.47 -0.09 (-0.58%)
As of 08/22/2025 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.89 +0.42 (+9.40%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$4.92 +0.04 (+0.72%)
As of 08/22/2025 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$6.93 +0.17 (+2.51%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$7.06 +0.13 (+1.86%)
As of 08/22/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.